Back to results
US 2022/0411364 A1Published application
Prostaglandin ep4 receptor antagonist compounds
AssigneeNxera Pharma UK Limitied
InventorsMiles Stuart Congreve, Nigel Alan Swain, Benjamin Whitehurst
Life of this patent
Estimating the term…
Abstract
The disclosures herein relate to novel compounds of formula (1): (1) and salts thereof, wherein A, X, R1, R2, R3, R4, R10 and R11 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EP4 receptors.
Claims26
A compound of Formula (1):
- or a salt thereof, wherein;
- A is selected from the group consisting of:
- X is an optionally substituted phenyl ring, an optionally substituted pyridyl ring or an optionally substituted imidazopyridine ring system;
- R1 and R2 are independently H or a C1-3 alkyl group which is optionally substituted with one or more fluorine atoms;
- or R1 and R2 are joined to form a 3-6 membered carbocyclic ring which is optionally substituted with one or more fluorine atoms;
- R3 is H, C1-3 alkyl or F;
- R4 is H or C1-3 alkyl;
- R8 is C1-3 alkyl or a C3-6 cycloalkyl ring;
- and either R10 and R11 are both methyl or R10 and R11 are joined to form a cyclobutyl ring.
6 more elements
Dependencies are inferred from the claim text.